We are live on ! Find out more
LXRX icon

Lexicon Pharmaceuticals

137 hedge funds and large institutions have $1.41B invested in Lexicon Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 44 increasing their positions, 33 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 33

15% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 20

1% more funds holding

Funds holding: 135137 (+2)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

0.4% less ownership

Funds ownership: 109.14%108.74% (-0.4%)

25% less capital invested

Capital invested by funds: $1.89B → $1.41B (-$478M)

88% less call options, than puts

Call options by funds: $1.77M | Put options by funds: $14.2M

Holders
137
Holders Change
+2
Holders Change %
+1.48%
% of All Funds
3.42%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
23
Increased
44
Reduced
33
Closed
20
Calls
$1.77M
Puts
$14.2M
Net Calls
-$12.4M
Net Calls Change
-$26.6M
Name Holding Trade Value Shares
Change
Change in
Stake
AG
1
Artal Group
Luxembourg
$707M
Fidelity Investments
2
Fidelity Investments
Massachusetts
$195M +$767K +51,936 +0.3%
BlackRock
3
BlackRock
New York
$59.4M +$2.55M +172,524 +4%
UL
4
Ulys LLC
New York
$53.1M
UBS AM
5
UBS AM
Illinois
$44M -$3.48M -235,952 -6%
Vanguard Group
6
Vanguard Group
Pennsylvania
$43.7M -$2.24M -151,486 -4%
UIM
7
USS Investment Management
United Kingdom
$43.1M
EAM
8
Eagle Asset Management
Florida
$34.5M -$421K -28,516 -1%
NMC
9
NEA Management Company
Maryland
$29.3M
State Street
10
State Street
Massachusetts
$25.7M +$1.89M +127,679 +6%
VOYA Investment Management
11
VOYA Investment Management
Georgia
$14.2M +$4.15M +281,112 +32%
Loomis, Sayles & Company
12
Loomis, Sayles & Company
Massachusetts
$12.1M +$1.52M +103,037 +12%
PA
13
Pinnacle Associates
New York
$11M +$2.69M +182,215 +25%
CLM
14
ClearBridge LLC (Maryland)
Maryland
$10.8M +$1.08M +73,380 +9%
KCM
15
Kornitzer Capital Management
Kansas
$9.42M +$11.3M +766,495 New
SGA
16
Sector Gamma AS
Norway
$9.06M +$1.7M +114,798 +18%
Bank of America
17
Bank of America
North Carolina
$7.63M +$6.06M +410,545 +195%
Northern Trust
18
Northern Trust
Illinois
$7.37M -$216K -14,643 -2%
Geode Capital Management
19
Geode Capital Management
Massachusetts
$5.32M +$145K +9,828 +2%
CCI
20
Columbus Circle Investors
$5.14M -$3.94M -266,588 -39%
Millennium Management
21
Millennium Management
New York
$4.72M -$4.56M -308,964 -45%
Parallax Volatility Advisers
22
Parallax Volatility Advisers
California
$4.31M +$5.18M +350,589 New
Deutsche Bank
23
Deutsche Bank
Germany
$4.06M +$196K +13,259 +4%
TRSOTSOK
24
Teachers Retirement System of the State of Kentucky
Kentucky
$3.96M -$1.28M -86,785 -21%
CS
25
Candriam SCA
Luxembourg
$3.6M

LXRX Hedge Fund Activity: Q3 2017 in Review

137 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q3 2017, worth a combined $1.41B — down 25% from $1.89B a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new LXRX positions and 20 closed out — a net gain of 3 holders — while 44 added to existing stakes and 33 trimmed.

The largest buyer was Kornitzer Capital Management, opening a new position worth an estimated $11.3M. The largest seller was Norges Bank, cutting an estimated $12.5M.

  • 137 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q3 2017, up from 135 in Q2 2017.
  • Funds reported $1.41B of Lexicon Pharmaceuticals stock for Q3 2017, down 25% quarter-over-quarter.
  • 23 funds opened new Lexicon Pharmaceuticals positions in Q3 2017 and 20 closed out, a net change of +3 holders.
  • The largest Lexicon Pharmaceuticals buyer in Q3 2017 was Kornitzer Capital Management, an estimated $11.3M added.
  • The largest Lexicon Pharmaceuticals seller in Q3 2017 was Norges Bank, an estimated $12.5M sold.

Based on aggregated 13F filings for Q3 2017.